473528-88-0

Basic information

• Product Name: 4-BROMO-1-METHYL-1H-PYRAZOLE-5-CARBALDEHYDE
• Synonyms: AKOS B007395;4-BROMO-1-METHYLPYRAZOLE-5-CARBOXALDEHYDE;4-BROMO-1-METHYL-1H-PYRAZOLE-5-CARBALDEHYDE;4-BROMO-2-METHYL-2 H-PYRAZOLE-3-CARBALDEHYDE;ART-CHEM-BB B007395;4-Bromo-1-methylpyrazole-5-carbaldehyde;4-Bromo-2-methylpyrazole-3-carbaldehyde;4-BroMo-1-Methyl-1H-pyrazole-5-carboxaldehyde, 97%
• CAS NO: 473528-88-0
• Molecular Formula: C₅H₅BrN₂O
• Molecular Weight: 189.01
• Mol File: 473528-88-0.mol
• Article Data: 6

Chemical Properties

• Melting Point: 102-103°C
• Boiling Point: 275.2 °C at 760 mmHg
• Flash Point: 120.2 °C
• Appearance: /
• Density: 1.73 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.48±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-BROMO-1-METHYL-1H-PYRAZOLE-5-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-1-METHYL-1H-PYRAZOLE-5-CARBALDEHYDE(473528-88-0)
• EPA Substance Registry System: 4-BROMO-1-METHYL-1H-PYRAZOLE-5-CARBALDEHYDE(473528-88-0)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 473528-88-0(Hazardous Substances Data)

Usage

General Description

4-Bromo-1-methyl-1H-pyrazole-5-carbaldehyde is a chemical compound with the molecular formula C6H6BrN3O. It is a yellow solid that is commonly used as an intermediate in the synthesis of pharmaceuticals and agricultural chemicals. 4-BROMO-1-METHYL-1H-PYRAZOLE-5-CARBALDEHYDE is known for its ability to react with a variety of reagents and undergo various chemical transformations, making it a versatile building block in organic synthesis. Its unique molecular structure and reactivity make it a valuable component in the development of new chemical compounds with potential applications in medicine and agriculture. However, it is important to handle 4-Bromo-1-methyl-1H-pyrazole-5-carbaldehyde with caution as it can be harmful if ingested, inhaled, or comes in contact with the skin or eyes.

Upstream product

• 27258-33-9 1-methyl-1H-pyrazole-5-carbaldehyde 
• 1269291-90-8 5-(dimethoxymethyl)-1-methyl-1H-pyrazole 

Downstream Products

• 327099-80-9 4-bromo-1-methyl-1H-pyrazole-5-carbonitrile 
• 153208-22-1 1-methyl-4-(phenylethynyl)-1H-pyrazole-5-carbaldehyde 
• 1609938-58-0 (5-benzyl-1-methyl-1H-pyrazol-4-yl)boronic acid 
• 1609937-75-8 [6-(5-benzyl-1-methyl-1H-pyrazol-4-yl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]-(1-methylpiperidin-4-yl)amine 
• 1276056-83-7 (4-bromo-1-methyl-1H-pyrazol-5-yl)methanol 

Relevant articles and documents

MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF

Hydantoin based compounds useful as inhibitors of matrix metalloproteinases (MMPs), particularly macrophage elastase (MMP-12) are described. Also described are related compositions and methods of using the compounds to inhibit MMP-12 and treat diseases mediated by MMP-12, such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, acute lung injury, idiopathic pulmonary fibrosis (IPF), sarcoidosis, systemic sclerosis, liver fibrosis, nonalcoholic steatohepatitis (NASH), arthritis, cancer, heart disease, inflammatory bowel disease (IBD), acute kidney injury (AKI), chronic kidney disease (CKD), Alport syndrome, and nephritis.

Lysophosphatidic acid receptor antagonists and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.

Synthetic and Mechanistic Investigation of an Oxime Ether Electrocyclization Approach to Heteroaromatic Boronic Acid Derivatives

A range of functionalized heteroaromatic boronic acid derivatives are readily accessed by a diboration/6π-electrocyclization sequence. This study revealed the surprising observation that there is a direct relationship between oxime ether stereochemistry and reactivity towards electrocyclization. Specifically, E-oxime ethers are found to be significantly more reactive than their Z-counterparts (stereochemistry relative to azatriene scaffold). In contrast, the configuration at the azatriene alkene terminus has little impact on reaction rates. Computational analysis offers a rationale for this observation; a Nlone pair→C=C π* orbital interaction lowers the energy of the transition state in the electrocyclization of E-oxime ethers. Finally, unreactive Z-oxime ethers can be converted to the corresponding heterocyclic products by a photolytically promoted E→Z isomerization and electrocyclization sequence.